Rare Cardiac Tumors

Tumors affecting the heart and great vessels are exceedingly rare conditions, encompassing tumors originating from these structures, metastatic tumors, and tumor-like lesions. Due to the critical locations of cardiac tumors and their hemodynamic impacts, most cardiac neoplasms are linked to significant morbidity and mortality. Our company specializes in delivering comprehensive preclinical research services dedicated to therapeutic development for rare cardiac tumors.

Overview of Rare Cardiac Tumors

Rare cardiac tumors are categorized as originating from the heart and great vessels or as secondary/metastatic tumors that invade neighboring organs like the lungs or occur in distant organs. Cardiac tumors are further classified into primary and secondary forms, they can manifest in the context of genetic syndromes such as tuberous sclerosis, Carney's complex, and multiple endocrine neoplasms (MEN).

Fig.1 Localization of cardiac tumor. (Bussani, R., et al., 2020)

Classification of Rare Cardiac Tumors

Cardiac tumors are categorized by their benign or malignant characteristics, as well as primary and secondary cardiac tumors. Primary cardiac tumors stem from the heart, with primary cardiac sarcoma being the most prevalent malignant primary cardiac tumor, while secondary tumors spread to the heart from elsewhere in the body. Lung cancer accounts for the highest incidence of metastatic cardiac tumors, followed by breast cancer, malignant melanoma, leukemia, and malignant lymphoma.

Fig.2 Classification of cardiac tumors. (Sankarasubramanian, S., et al., 2022)

Therapeutics Development for Rare Cardiac Tumors

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

With a team of experienced researchers and experts in the field of cardiology and oncology, we offer a range of tailored solutions to support the advancement of novel therapeutics targeting these complex conditions. We utilize cutting-edge technologies and methodologies to provide diagnostic, therapeutic, and animal model development services, aiding clients in progressing their cardiovascular disease research.

Types of Rare Cardiac Tumors

Therapeutic and Animal Model Development Services

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein

Animal Model Development Services

• Chemical-induced Model
• Diet-induced Model
• Genetically Engineered Model
• Immunogenicity Model
• Surgical Model
• Transplant Model

Furthermore, we offer pharmacokinetic research and drug safety evaluation services to support the development of potential therapeutics for rare cardiac tumors. By collaborating with us, clients access advanced methodologies, state-of-the-art technologies, and a comprehensive one-stop solution for preclinical research. If you are interested in our services, please feel free to contact us at your convenience.

References

• Bussani, Rossana et al. "Cardiac Tumors: Diagnosis, Prognosis, and Treatment." Current cardiology reports 22.12 (2020): 169.
• Sankarasubramanian, Sivaramasundaram et al. "Genetic insights into cardiac tumors: a comprehensive review." Medical oncology (Northwood, London, England) 39.11 (2022): 164.